

August 13, 2021

NOTICE

The Board of Directors of the Kaweah Delta Health Care District will meet in a Quality Council Committee meeting at 7:00AM on Thursday, August 19, 2021, in the Kaweah Health Lifestyle Fitness Center Conference Room, 5105 W. Cypress Avenue, Visalia, CA 93277.

The Board of Directors of the Kaweah Delta Health Care District will meet in a Closed Quality Council Committee at 7:01AM on Thursday, August 19, 2021, in the Kaweah Health Lifestyle Fitness Center Conference Room, 5105 W. Cypress Avenue, Visalia, CA 93277, pursuant to Health and Safety Code 32155 & 1461.

The Board of Directors of the Kaweah Delta Health Care District will meet in an open Quality Council Committee meeting at 8:00AM on Thursday, August 19, 2021, in the Kaweah Health Lifestyle Fitness center Conference Room, 5105 W. Cypress Avenue, Visalia, CA 93277.

All Kaweah Delta Health Care District regular board meeting and committee meeting notices and agendas are posted 72 hours prior to meetings in the Kaweah Health Medical Center, Mineral King Wing entry corridor between the Mineral King lobby and the Emergency Department waiting room.


The disclosable public records related to agendas are available for public inspection at Kaweah Health Medical Center – Acequia Wing, Executive Offices (Administration Department) {1st floor}, 400 West Mineral King Avenue, Visalia, CA and on the Kaweah Delta Health Care District web page https://www.kaweahhealth.org.

KAWEAH DELTA HEALTH CARE DISTRICT Garth Gipson, Secretary/Treasurer

Cindy Moccio

Cindy Moccio Board Clerk, Executive Assistant to CEO

DISTRIBUTION: Governing Board, Legal Counsel, Executive Team, Chief of Staff <u>http://www.kaweahhealth.org</u>



KAWEAH DELTA HEALTH CARE DISTRICT BOARD OF DIRECTORS QUALITY COUNCIL

Thursday, August 19, 2021 5105 W. Cypress Avenue Kaweah Health Lifestyle Fitness Center Conference Room

ATTENDING: Board Members; David Francis – Committee Chair, Mike Olmos; Gary Herbst, CEO; Keri Noeske, RN, BSW, DNP, Vice President & CNO; Monica Manga, MD, Chief of Staff; Daniel Hightower, MD, Professional Staff Quality Committee Chair; Tom Gray, MD, Quality and Patient Safety Medical Director; Sandy Volchko DNP, RN CLSSBB, Director of Quality and Patient Safety; Ben Cripps, Vice President, Chief Compliance and Risk Management Officer; Evelyn McEntire, Director of Risk Management; and Michelle Adams, Recording.

OPEN MEETING – 7:00AM

- 1. Call to order David Francis, Committee Chair
- 2. Public / Medical Staff participation Members of the public may comment on agenda items before action is taken and after it is discussed by the Board. Each speaker will be allowed five minutes. Members of the public wishing to address the Board concerning items not on the agenda and within the jurisdiction of the Board are requested to identify themselves at this time. For those who are unable to attend the beginning of the Board meeting during the public participation segment but would like to address the Board, please contact the Board Clerk (Cindy Moccio 559-624-2330) or cmoccio@kaweahhealth.org to make arrangements to address the Board.
- 3. Approval of Quality Council Closed Meeting Agenda 7:01AM
 - Quality Assurance pursuant to Health and Safety Code 32155 and 1461 Daniel Hightower, MD, and Professional Staff Quality Committee Chair;
 - **Quality Assurance** pursuant to Health and Safety Code 32155 and 1461 Evelyn McEntire, *RN, BSN, Director of Risk Management and Ben Cripps, Vice President & Chief Compliance and Risk Management Officer.*
- 4. Adjourn Open Meeting David Francis, Committee Chair

CLOSED MEETING – 7:01AM

- 1. Call to order David Francis, Committee Chair & Board Member
- **2.** <u>Quality Assurance pursuant to Health and Safety Code 32155 and</u> 1461 Daniel Hightower, *MD, and Professional Staff Quality Committee Chair*

Thursday, August 19, 2021 – Quality Council

Page 1 of 2

- **3.** <u>Quality Assurance pursuant to Health and Safety Code 32155 and 1461</u> Evelyn McEntire, RN, BSN, Interim Director of Risk Management, and Ben Cripps, Chief Compliance Officer.
- 4. Adjourn Closed Meeting David Francis, Committee Chair

OPEN MEETING – 8:00AM

- 1. Call to order David Francis, Committee Chair
- 2. Public / Medical Staff participation Members of the public wishing to address the Committee concerning items not on the agenda and within the subject matter jurisdiction of the Committee may step forward and are requested to identify themselves at this time. Members of the public or the medical staff may comment on agenda items after the item has been discussed by the Committee but before a Committee recommendation is decided. In either case, each speaker will be allowed five minutes.
- **3.** Written Quality Reports A review of key quality metrics and actions associated with the following improvement initiatives:
 - 3.1. <u>Central Line Associated Blood Stream Infection (CLABSI) and MRSA Quality</u> <u>Focus Team Report</u>
- <u>Cardiac Surgery Quality Update</u> A review of key quality indicators and actions through the Society of Thoracic Surgeons (STS) Data Registry. *Leheb Araim, MD, Medical Director* of Cardiac & Thoracic Surgery.
- <u>Cardiology Quality Update</u> A review of key quality indicators and actions through the American College of Cardiology (ACC) Data Registry. *Ashok Verma, MD, Medical Director Cardiac Cath Lab.*
- 6. <u>Update: Clinical Quality Goals</u> A review of current performance and actions focused on the fiscal year 2021 clinical quality goals. *Sandy Volchko, RN, DNP, Director of Quality and Patient Safety.*
- 7. Adjourn Open Meeting David Francis, Committee Chair

In compliance with the Americans with Disabilities Act, if you need special assistance to participate at this meeting, please contact the Board Clerk (559) 624-2330. Notification 48 hours prior to the meeting will enable the District to make reasonable arrangements to ensure accessibility to the Kaweah Delta Health Care District Board of Directors committee meeting.

Central Line Blood Stream Infection (CLABSI) Quality Focus Team Report August 2021

Amy Baker, Director of Renal Services (Chair) Emma Camarena, Advanced Practice Nurse (Co-Chair) Shawn Elkin, infection Prevention Manager (IP Liaison)

f | 🖸 | 🍠 | 🞯 | kaweahDelta.org



Prepared By: Cindy Vander Schuur


October 2020

and ackground Team Quality Focus Ω Event Kaizen CLABSI

Background: Patients are acquiring CLABSIs at rates that exceed national benchmarks. The CLABSI SIR from July 2019 to December 2019 was 1.47 with a goal (CMS 50th percentile) of \leq 0.784; the number of CLABSIs was higher than expected (9 observed, 6 expected). CLABSIs result in poor outcomes for patients, a negative public perception of care through publically reported safety scores and financially impact the organization through HAC and VBP programs as well as increased treatment costs and length of stay.


Current State (Kaizen Event) Review -

- Days between CLABSI from 4/2018 to 4/2020 is 18.74.
- · CLABSIs are associated with both insertion practices and maintenance practices
- CLABSIs have not increased because we have more central lines or insert them under emergent circumstances
- · We do not have consistency with best practices in CLABSI prevention
- No standard MD training on CLABSI prevention training
- The "Vital Few" are:
 - Central Line site: IJ or Femoral
 - Bath not received
 - · Line necessity was not addressed
 - Hemodialysis
 - Expired peripheral IV •
- CLABSIs are not isolated to one unit or unit type
- The weekly HAI audit (for best practices) has not helped consistency in bundle practices or reduced CLABSI



Action Plan: Goal CLABSI SIR ≤0.633	(new) and Mean Days Between CLABSI > 4	0.5
	(new) and mean Days Detween OLADOR -	

Improvement Strategy	Who?	When?
Line Necessity –Implementation of interventions delayed due to COVID-19 pandemic	Emma C. Joetta D.	March 31, 2020 (TPN orders 7/2020)
Bundle Practice-Implementation of interventions delayed due to COVID-19 pandemic	Amy Baker	March 31, 2020
Education-Implementation of interventions delayed due to COVID-19 pandemic priorities	Eileen P. Enri S.	March 31, 2020 (Comp Fair 6/20)
Blood Cultures: The Culture of Culturing	Dr. Gray & Shawn Elkin	
Leadership Standard Work	Mary Laufer	
 Improve location and par of central line supplies Include in manager communication plan; Include in RN & CNA education that they need to follow up with CN or manager that PAR level needs to be adjusted; also talk to manager & central distribution 	Kaizen Team Education Team	
Email Take-Always after CLABSI committee review of events	Amy Baker	
Insertion: New site = New kit to be included with MD/resident education with Dr. LeDonne—Conference cancelled due to COVID-19 pandemic.	Dr. Gray Shawn Elkin	



Post Kaizen- Gemba Data

CLABSI Committee Dashboard

	Denehmerk													
Measure Description	Benchmark/ Target	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21	Mar-21	Apr-21	May-21
OUTCOME MEASURES														
Number of CLABSI	0	0	5	2	1	2	0	1	2	1	2	0	0	1
FYTD SIR	≤ 0.633		1.63			1.28*			1.2*			0.933		
PROCESS MEASURES CL Gemba Rounds					1									
% of pts with bath within 24 hrs	99%	78%	80%	84%	88%	88%		95%	96%	96%	96%	96%	97%	93%
% of CL with valid rationale order	100%	93%	97%	96%	95%	96%		98%	98%	97%	99%	98%	98%	98%
% of CL dressings clean, dry and intact	100%	92%	95%	91%	92%	95%		97%	95%	94%	97%	95%	95%	97%
% of CL that had drsg change no > than 7 days	100%	90%	90%	89%	96%	98%		98%	98%	99%	99%	99%	99%	98%
% of patients with proper placed gardiva patch	100%	81%	93%	90%	89%	92%		93%	94%	94%	93%	95%	94%	94%
% of CL pts with app & complete documentation	100%	81%	86%	86%	87%	87%		92%	91%	93%	95%	90%	91%	94%
# of Pt Central Line days rounded on	n/a	1050	1315	1194	1087	1372		1084	1194	1067	1010	1179	1198	968
*SIR manually calculated			Bette	r than T	arget		vithin 10% ug: Within Target	of Target 15% of		not mee	t Target			

Total Number of Patient Central Line Days Rounded on = 13,718

Continued focus in areas on CLABSI reduction – prioritizing the initiatives.

Improvements from first 3 months of Gemba vs last 3 months:

Bath within 24 hrs: 81% to 95% CL with order: 95% to 98% Dressing Clean: 92% to 96% Dressing change: 90% to 99% Gardiva Patch: 88% to 94% Complete documentation: 83% to 92%




Clabsi QFT- Plans for Improvement

- Subcommittees have formed to help reduce different aspects of CLABSI
 - Culture of Culturing Committee- work on reduce number of pan culturing and discuss TPN utilization related to CLABSI's
 - HAI Review Committee- Review each CLABSI case to identify learning opportunities, barriers and identify root causes
 - MRSA Subcommittee- develop plan to address MRSA infections. Discussing nasal decolonization

In addition to subcommittees the CLABSI QFT has been

- Reviewing unit specific action plans to address CLABSI's- for example 4 North auditing compliance of CHG bathing for high risk infection patients with central lines
- Remediating education as needed
- Ensuring materials are available on the units for communication
- Working on Power Plan to create ease of use and understanding
- Update policy with Lippincott links so staff can see video's of central line dressing changes
- Working with shared governance teams to get feedback on barriers facing each unit

End of Fiscal Year Performance






QUESTIONS?



Cardiac Surgery Data 2020 Risk-Adjusted Data



DATA ANALYSES BY THE SOCIETY OF THORACIC SURGEONS NATIONAL ADULT CARDIAC SURGERY DATABASE

*Comparison STS reporting period 01/01/2020 through 12/31/2020 20/84

Star Ratings 2020

Isolated Coronary Artery Bypass Grafting

Star Ratings are only calculated ending Q2 & Q4 each year

The S of The Surge	Gociety oracic eons		S	STS CABG Composite Quality Rating Participant: 30045 STS Period Ending Dec 2020						
Domain	Rating	Partic	cipant	STS						
		Score	98% CI	Score	Min - Max	10th	50th	90th		
Overall	**	96.57%	(94.98-97.77)	96.68%	(91.08-98.92)	95.12%	96.86%	97.98%		
Absence of Mortality	**	97.03%	(94.78-98.50)	97.42%	(92.79-99.19)	96.22%	97.56%	98.44%		
Absence of Morbidity	**	90.13%	(85.52-93.69)	89.31%	(73.20-96.33)	84.71%	89.79%	93.25%		
Use of IMA	**	98.65%	(96.02-99.77)	99.34%	(88.84-99.99)	98.56%	99.65%	99.92%		
Medications	**	96.98%	(93.25-99.11)	94.37%	(44.56-99.96)	85.92%	97.18%	99.47%		
As As As Bet lote: Each participu everity) compared pply only to their c ase-mix.	Expected. Participant's tter than Expected. Par ant's composite score and with overall, national STS tase-mix, they cannot be o	s performance is not stati ticipant's performance is I star rating are an estimate Soutcomes for a similar mix	s significantly worse than ex istically different than expect significantly better than exp of their performance for their s of patients. Because a participu omposite score and star rating time.	cted for their specific ca pected for their specific specific case-mix (e.g., pa ant's composite score and	ase-mix. : case-mix. tient acuity and ! star rating					

Star Ratings 2020 Aortic Valve Replacement

Star Ratings are only calculated ending Q2 & Q4 each year

f Th	Society oracic eons	STS AVR Composite Quality Rating Participant: 30045 STS Period Ending Jun 2020								
Domain	Rating	Pa	rticipant			STS				
		Score	95% CI	Score	Min - Max	10th	50th	90th		
Overall	**	96.5%	(94.6-97.8)	95.7%	(86.1-98.6)	93.6%	95.9%	97.4%		
Absence of Mortality	**	98.2%	(96.6-99.2)	98.0%	(93.0-99.5)	96.8%	98.1%	98.9%		
Absence of Morbidity	**	90.9%	(86.9-94.1)	89.9%	(77.1-95.9)	86.2%	90.3%	93.1%		
★ ★ As ★ ★ ★ Be Note: Each particip severity) compared apply only to their of case-mix.	Expected. Participan tter than Expected. Pa ant's composite score an with overall, national Si case-mix, they cannot be	t's performance is not si articipant's performance nd star rating are an estima TS outcomes for a similar n	e is significantly worse tha tatistically different than ex t is significantly better than ate of their performance for th nix of patients. Because a part e composite score and star rat	pected for their specifi expected for their spec eir specific case-mix (e.g., icipant's composite score	c case-mix. :ific case-mix. , patient acuity and and star rating					

Star Ratings 2020 CABG w/ Aortic Valve Replacement

Star Ratings are only calculated ending Q2 & Q4 each year

The Society of Thoracic Surgeons		STS AVR + CABG Composite Quality Rating Participant: 30045 STS Period Ending Dec 2020							
Domain	Rating	Participant							
		Score	95% CI	Score	Min - Max	10th	50th	90th	
Overall	**	92.61%	(89.24-95.28)	92.34%	(79.23-97.60)	88.73%	92.78%	95.39%	
bsence of Mortality	**	95.77%	(92.43-98.00)	96.05%	(86.09-99.10)	93.71%	96.40%	97.95%	
osence of lorbidity	**	84.22%	(77.54-89.77)	83.12%	(62.60-93.74)	76.73%	83.68%	88.82%	
★★ As	Expected. Participant	's performance is not st	e is significantly worse that atistically different than ex is significantly better than	pected for their specif	ic case-mix.				
te: Each participo erity) compared oly only to their c e-mix.	nnt's composite score an with overall, national ST ase-mix, they cannot be	d star rating are an estima 'S outcomes for a similar m	te of their performance for the ix of patients. Because a parti composite score and star rati	eir specific case-mix (e.g cipant's composite score	., patient acuity and and star rating				

Healthgrades Specialty Clinical Quality Awards & Ratings

Hospital Quality Awards



America's 250 Best Hospitals Award™ (2021, 2020, 2019) Top 5% in the nation for consistently delivering clinical quality

Specialty Clinical Quality Awards




America's 50 Best Hospitals for Cardiac Surgery Award[™] (2021, 2020, 2019) Superior clinical outcomes in heart bypass surgery and heart valve surgery



America's 100 Best Hospitals for Cardiac Care Award[™] (2019)

Superior clinical outcomes in heart bypass surgery, coronary interventional procedures, heart attack treatment, heart failure treatment, and heart valve surgery

All Operative Mortality¹ Risk Adjusted in Color



Kaweah Delta Medical Center


2020 O/E risk-adjusted = 1.3

• STS Comparison reporting period 1/1/2020 through 12/31/2020

1- Includes all 7 Major Procedure Categories (CABG, AVR, AVR+CABG, MVR, MVR+CABG, MVP, MVP+CABG) Excludes Other category procedures 25/84

CABG Operative Mortality

Risk Adjusted in Color




Kaweah Delta Medical Center

2020 O/E risk-adjusted = 1.4


• STS Comparison reporting period 1/1/2020 through 12/31/2020

KH Patient Population



CABG Re-Operation¹

Risk Adjusted in Color



Kaweah Delta Medical Center

2020 O/E risk-adjusted = 1.1

STS Comparison reporting period 1/1/2020 through 12/31/2020


¹Surgeries include Reoperation for bleeding/tamponade, valvular dysfunction, unplanned coronary artery intervention, aortic reintervention or other cardiac reas/9/84

Quality Initiative: Intra-operative Patient Safety

- Time out performed with entire surgical team
- Surgeon led briefing on procedure with entire surgical team
- Minimize trips to the Sterile Core by Nursing staff
- Minimize OR traffic (i.e.: switching staff for breaks)
- Noise reduction implemented:
 - Discussions about current surgical case only
 - Avoid conversations about other cases or other issues
 - Music to be calming and at a lower volume
 - All phones & beepers at the Nurses desk
- Perfusion check list completed each case


Blood Usage - Average Units / Pt. receiving products¹

(No National Comparison Data)



Kaweah Delta Medical Center

¹ All STS surgeries – Includes any blood products given Intra-op and Post-op (Excludes patients that did not receive any blood products; excludes pre-op Hgb<8 and Emergent/Salvage) *Data is not reported on the National Outcomes Report



CABG Intra & Post-Op Red Blood Cell Usage¹

Kaweah Delta Medical Center

2020 O/E = 1.1


STS Comparison reporting period 1/1/2020 through 12/31/2020

¹Surgeries where at least one unit of Red Blood Cell was given Intra-and/or Post-operatively. *Excludes Fresh Frozen Plasma, Platelets and Cryoprecipitate* 31/84

Quality Initiative: Bleeding, blood usage


- Quarterly review of blood usage throughout Pt. stay
- TEG coagulation monitoring
- Antifibrinolytic agents
- Heparin monitoring
- Heparin coated circuits
- Hemostasis achieved during procedure
- Cell saver utilized during surgery
- Restrictive transfusion criteria
- Surgeon approval of each transfusion
- Treatment of pre-operative anemia or transfusion as needed

KH Patient Population



*Comparison reporting period 1/1/2020 through 12/31/2020 – Isolated CABG cases ONLY 33/84

CABG Post-Op Renal Failure¹ Risk Adjusted in Color



Kaweah Delta Medical Center

2020 O/E risk-adjusted = 2.3


- STS Comparison reporting period 1/1/2020 through 12/31/2020
- ¹ Excludes patients with preoperative dialysis or preoperative Creatinine ≥ 4

Quality Initiative: Renal Failure Prevention

- Risk factor evaluation pre-operatively
- Timing of surgery considered
- Diabetes control
- Liberal hydration
- Intra-operative blood flow & pressure controlled by perfusion and anesthesia
- Blood pressure management peri-operatively

CABG Prolonged Ventilation

Risk Adjusted in Color



2020 O/E risk-adjusted = 1.0

• STS Comparison reporting period 1/1/2020 through 12/31/2020

Quality Initiative: Prolonged Ventilation

- Monthly audit & analysis of prolonged ventilation times and delayed Extubation cases due to medical necessity
- Action Plan for 100% compliance in completing Cardiac Extubation Tool ~ followed daily by CVICU nurse manager
- Sedation and Analgesia to be used in an appropriate and conservative manner
 - Avoid Benzodiazepines and narcotic drips
 - To illicit calm awakening utilize Propofol & precedex drips when medically necessary
- Address ventilation time of each Pt. in rounds and shift reports by RN, RT & MD
- Promote Respiratory Therapy Education Tool for patients
- Review of Anesthesia Protocols
 - Positive Base excess or > -2.0 on CVICU arrival
 - Core Temperature > 36.0°C on CVICU arrival

CABG Post Op Permanent Stroke Risk Adjusted in Color 3.0% 2.5% 2.0% Goal 1.8% 1.5% 1.4% 1.4% 1.0% 1.1% 0.5% 0.0% 0.0% 2017 2018 2019 2020 STS* n=0/182 n=3/189 n=4/199 n=2/167

Kaweah Delta Medical Center

2020 O/E risk-adjusted = 0.8


Percent of Patients

• STS Comparison reporting period 1/1/2020 through 12/31/2020

38/84

Quality Initiative: Stroke prevention

- Risk factor, neurological evaluation
- TEE, CT of the aorta with evaluation as needed
- Carotid Doppler ~ Ultrasound
- Invox cortical brain monitoring
- Intraoperative blood flow & pressure control by perfusion and anesthesia
- Intraoperative temperature control



CABG Post Op Deep Sternal Wound Infection Risk Adjusted in Color

2020 O/E risk-adjusted = 0


• STS Comparison reporting period 1/1/2020 through 12/31/2020

40/84

Quality Initiative: Infection Prevention

- Glucose control w/ Glucommander insulin drip or subcutaneous
- Two Chlorhexidine baths prior to surgery
- Chlorhexidine mouth wash used morning of surgery
- MRSA screening of each patient
- Terminal cleaning of operating rooms monitored daily
- Disposable ECG monitoring cables on each patient
- Use of Early closure technique for vein harvest incisions
- Vancomycin paste for sternal application
- Prevena suction dressing applied to sternum
- Prophylactic antibiotic treatment for 48 hours
- Early removal of central lines and Foley catheter


CABG Post Op Length of Stay >14 Days Risk Adjusted in Color



2020 O/E risk-adjusted = 1.1


STS Comparison reporting period 1/1/2020 through 12/31/2020
 Post-operative Length of Stay: Long Stay is greater than 14 days (PLOS > 14 Days)

KH Radial Artery Usage




Comparison reporting period - 1/1 through 12/31 of each year – Isolated CABG cases ONLY 43/84

KH Patient Population



*Comparison reporting period 1/1/2020 through 12/31/2020 – Isolated CABG cases ONLY 44/84


CABG Skin-to-Skin and Bypass Pump Durations ¹



2020 O/E Pump Times = 1.4

STS Comparison reporting period 1/1/2020 through 12/31/2020

Cardiothoracic Surgery Volumes¹



¹ Cardiac surgery as defined per STS database. Includes all 7 Major Procedure Categories (CABG, AVR, AVR+CABG, MVR, MVR+CABG, MVP, MVP+CABG) + Other Heart only procedures.

U.S. News & World Report



- Kaweah Delta Medical Center is the Highest Ranked Hospital in the Central Valley for Cardiology & Heart Surgery
- Kaweah Delta Medical Center achieved the Recognition of being Ranked in California. Only three institutions among the 46 Central Valley Hospitals and Clinics reviewed by U.S. News & World Report achieved this honor



Quality Improvement for Institutions




Kaweah Health Medical Center PCI Data Quality Analysis

Q2 2020 – Q1 2021

Green = In the Top 10% of the Nation Yellow = Better or Equal to the National Average Red = Worse than National Average Gray = Non-Risk Adjusted Value (for Reference only)

*Comparison reporting period Varies per Metric

PCI In-Hospital Mortality Rate¹ Risk Adjusted^{InColor} (All patients)



R4Q Risk Adjusted O/E = 0.9

¹ PCI in-hospital mortality rate for all patients, risk adjusted. Exclusions include patients with a discharge location of "other acute


care hospital." (ref: 4739, 4736)

^{*}Comparison reporting period is 04/01/20 through 03/31/21

^{49/84}


PCI In-Hospital Mortality Rate¹ Risk Adjusted (All patients)

TWO-YEAR TRENDING



¹ PCI in-hospital mortality rate for all patients, risk adjusted. Exclusions include patients with a discharge location of "other acute care hospital." (ref: 4739, 4736)

PCI In-Hospital Mortality Rate¹ Risk Adjusted^{InColor} (STEMI patients)




R4Q Risk Adjusted O/E = 0.85

¹ PCI in-hospital mortality rate for STEMI Pt.'s. (ref: 4740, 4734)

* Comparison reporting period is 04/01/20 through 03/31/2151/84

PCI In-Hospital Mortality Rate¹ Risk Adjusted (STEMI patients)


TWO-YEAR TRENDING



52/84

¹ PCI in-hospital mortality rate for STEMI Pt.'s. (ref: 4740, 4734)

PCI In-Hospital Mortality Rate¹ Risk Adjusted^{InColor} (NSTEMI, unstable angina, electives)




R4Q Risk Adjusted O/E = 1.02

¹ PCI in-hospital mortality rate for all patients Excluding STEMI. Exclusions include patients with a discharge location of "other acute care hospital," (ref; 4741, 4735)

* Comparison reporting period is 04/01/20 through 03/31/21

PCI In-Hospital Mortality Rate¹ Risk Adjusted (NSTEMI, unstable angina, electives)

TWO-YEAR TRENDING



¹ PCI in-hospital mortality rate for all patients Excluding STEMI. Exclusions include patients with a discharge location of "other acute care hospital." (ref: 4741, 4735)

STEMI Triage Guidelines Thoughtful Pause

- Should go to CVICU first, not the Cath Lab
 - Cardiac Arrest with $CPR \ge 20$ minutes and un/minimally responsive
 - Cardiogenic Shock, age ≥ 80
 - STEMI \geq 24 hours without Chest Pain
 - Excess risk of bleeding (e.g. active internal bleed, ICH <3 mos, Hct <22, PLT <30K)
 - Altered Mental Status
 - Apparent sepsis or other conditions (other than pure cardiogenic shock) that would markedly increase the risk of dying within 30 days
 - Pre-existing DNR / No Code Status
 - Consider lytic agents for symptoms < 3 hours, anticipated DTB time > 120 minutes and low risk of bleeding
 - These are intended as guidelines, not to supersede clinical judgement

Adopted from The Cleveland Clinic Heart Institute: Triage Guidelines for STEMI patients.

55/84

Predicted Mortality Risk Factors

- STEMI
- Age >70
- BMI
- Cerebral Vasc. Disease
- Peripheral Vasc. Disease
- Chronic Lung Disease
- Previous PCI
- NIDDM
- IDDM
- GFR
- Renal Failure / Dialysis

- Ejection Fraction
- Cardiogenic Shock
- NYHA Class I/II/III
- NYHA Class IV
- Cardiac Arrest
- Thrombosis w/in 1 month
- PCI of Prox LAD
- PCI of LM
- >=2VD
- Total Chronic Occlusion

Quality Initiative:

Treatment Algorithm for Invasive Cardiac Procedures

Targeted Temperature Management

 Immediate hypothermia measures to be implemented on cardiac arrest patients

- 12-Lead ECG must be done within 10 minutes of arrival to hospital
- ACT initiated (Do not delay cooling measures)
 - <u>Assessment</u> for unfavorable resuscitation features
 - <u>Consultation</u> between ED, Critical Care and Cardiology physicians
 - Transport to CathLab urgently when consensus reached

Quality Initiative: Vitally Important Steps

- Physician collaboration & coordination between departments is required
- Cardiologist must participate in all thoughtful pause discussions
- ED physician and Cardiologist will consult with an Intensivist as needed for difficult cases
- Intensivist will respond to the ED for thoughtful pauses as requested
- Thoughtful pause must be documented in patient's EMR
 by a physician
- Families must be given aggressive treatment options with their corresponding prognosis or futility
- Honest communication between all parties required to maintain transparency and trust

PCI Radial Artery Access




R4Q O/E = 0.7

(ref: NCDR Detail Line 4163)

* Comparison reporting period is 04/01/20 through 03/31/21

Immediate PCI for STEMI (in minutes)¹




R4Q O/E = 0.9

¹ Median time frame from hospital arrival to immediate PCI for STEMI pts in minutes. Exclusions: Patients transferred in from

another acute care facility; Reasons for delay does not equal none. N= pt.'s receiving PCI within 90 minutes. (ref:4448)

* Comparison reporting period is 04/01/20 through 03/31/21 60/84

Immediate PCI for STEMI Transfers (in minutes)¹



R4Q O/E = 1.2

¹ Median time from ED arrival at STEMI transferring facility to immediate PCI at STEMI receiving facility among transferred

patients (excluding reason for delays); Reasons for delay does not equal none. (ref:4452, 10888)


* Comparison reporting period is 04/01/20 through 03/31/21 61/84

Quality Initiative:

Best Practice in Door to Balloon

- 4 Staff on call at all times with crew response time of 20 minutes
- Recognition of staff with a monthly fastest Door to Balloon award to incentivize staff
- Cardiac Alerts to be called at the time of leaving transferring hospitals
- ED EKG to be placed in EMR or Tracemaster
- STEMI taskforce with ED, Quality, Cath Lab to review ED STEMI hand off including STEMIs called in the field and from other facilities
- Cardiac Alerts called within 10 minutes of ED arrival unless Thoughtful Pause is documented in the EMR

Stroke Post PCI¹



R4Q O/E = 1.4


¹ Exclusions: Patients with an Intervention this admission (Surgery, EP, Other); Pt's discharged to Other Acute Care Facility (ref: 4235) * Comparison reporting period is 04/01/20 through 03/31/294

Quality Initiative:

Stroke Recognition and Treatment

- Assess Stroke Risk factors in PCI for each patient
 - Age, gender, history of CVA, End Stage Renal Disease, Diabetes, Hypertension, Peripheral Vascular Disease, Smoking, Congestive Heart Failure, Atrial Fibrillation, CABG surgery or emergent PCI
- Rapid recognition of stroke symptoms in Cath Lab
- Use of the clear protocol for recognition and interventions will facilitate efficient care in the unlikely event of a stroke in Cath Lab

Acute Kidney Injury¹ Post PCI Risk Adjusted^{InColor}



R4Q Risk Adjusted O/E = 0.86


¹ Proportion of pt's with a rise of serum creatinine of > 50% or ≥0.3 mg/dL over the pre-procedure baseline; all pt's w/ New Requirement for Dialysis. Exclusions: pt's on dialysis pre-procedure; pt's second PCI within this episode of care; same day discharges. (ref: 4882) * Comparison reporting period is 04/01/29 through 03/31/21

Quality Initiative:

Contrast Induced Nephropathy

- Renal impairment = estimated glomerular filtration rate ≤ 60mL/min
- Hydration Needs
 - <u>Pre procedure</u>: Normal Saline at 250 ml/hour to be started upon arrival
 - o <u>Intra procedure</u>:
 - LVEDP <18 \rightarrow NS 500 mL/hr for 4 hours
 - LVEDP >19 \rightarrow NS 250 mL/hr for 4 hours
 - Post procedure: Normal Saline at 250 ml/hour for 6-24 hours
- For outpatients, an increase in oral hydration is encouraged the day before arrival. The patients are encouraged to drink clear liquid up to 2 hours before procedure
- Post procedure labs must be ordered
- Metabolic panel ordered one day post procedure
- Track and Report contrast utilization for Diagnostic and Interventional procedures

Transfusion Post-PCI of RBCs¹




R4Q O/E = 1.0

¹ Proportion of pt's who receive a transfusion of whole blood or RBCs during or after, but within 72 hours of PCI procedure. Exclusions: Patients on dialysis; EP study or CABG or other major surgery during the same admission; Pt.'s with a pre-procedure hemoglobin <8g/dL or no value. (ref: 4288) * Comparison reporting period is 04/01/20 through 03/31/21 Guidelines for Usage of Blood Products (Release Criteria) Policy Number: TR-00036 / Date Approved: 09/08/2015

APPROPRIATE USE OF RED BLOOD CELLS

- A. Pre-transfusion hematocrit of less than 24% or hemoglobin less than 8 grams/dl.
- B. Transfusion may be administered when hemoglobin levels are 8-10 grams/dl in the following circumstances:
 - 1. Acute Blood Loss/Active Bleed
 - 2. Presence of Symptomatic Anemia
 - 3. HGB <9 w/ Chemotherapy
 - 4. HGB <10 w/ Radiation Treatment

Risk Standardized Bleeding Rate¹




R4Q O/E = 1.4 ¹ Pt's with a Bleeding event defined as 1) occurring within 72 hours of procedure (Bleeding at access site, hematoma at access site, retroperitoneal bleed, GI, GU or any transfusion) 2) occurring during hospitalization (hemorrhagic stroke, tamponade, Hgb drop \geq 4 g/dL requiring transfusion, or a procedural intervention/surgery to reverse/stop or correct the bleeding) Exclusions: subsequent PCI procedures, death w/in 24 hours, CABG this hospitalization, transfusion in presence of mechanical support. (ref: 4934) * Comparison reporting period is 04/01/20 through 03/31/21

Quality Initiative: Bleeding Protocol

- Establish a vascular site protocol in accordance with SCAI safe femoral access guidelines
 - 1. Radial first
 - 2. Use of ultrasound guidance
 - 3. Use of fluoroscopy to mark the femoral head
 - 4. Use of micro puncture needle

ASA Prescribed at DC¹




R4Q O/E = 1.0

¹ Proportion of pt.'s (without a documented contraindication) with a PCI attempted or performed that were prescribed aspirin at discharge. Exclusions: pt.'s that were discharged on Comfort Measures only; discharged to "Other acute care hospital", "Hospice",

"Left against medical advice (AMA)" or deaths. (ref: 4702) * Comparison reporting period is 04/01/20 through 03/31/21 71/84

P2Y12 Inhibitor Prescribed at DC¹




R4Q O/E = 1.0

¹ Proportion of pt.'s (without a documented contraindication) with a cardiac stent placed that were prescribed a thienopyridine/P2Y12 inhibitor at discharge. Exclusions: pt.'s that were discharged on Comfort Measures only; discharged to "Other acute care hospital",

"Hospice", "Left against medical advice (AMA)" or deaths (ref: 72/84

* Comparison reporting period is 04/01/20 through 03/31/21

Statins Prescribed at DC¹




R4Q O/E = 1.0

¹ Proportion of pt.'s (without a documented contraindication) with a PCI attempted or performed that were prescribed a statin at discharge. Exclusions: pt.'s that were discharged on Comfort Measures only; discharged to "Other acute care hospital", "Hospice", "Left against medical advice (AMA)" or deaths. (ref: 4707) * Comparison reporting period is 04/01/20 through 03/31/21

Quality Initiative: Discharge Medications

- Develop and implement PCI specific discharge order set
- Re-educate Hospitalists and Nurse Practitioners on importance of specific discharge medications in this patient population and utilization of new Order Set.
- Track utilization of order set
- Contact Lead Hospitalist or Nurse Practitioner with all fallouts and track
- Improving Clinical documentation in the Discharge Summary of any contraindications
- Improving Clinical documentation in the Discharge Summary clarifying any pending diagnosis (i.e. possible NSTEMI, possible MI)

Post-PCI Length of Stay¹ – STEMI




R4Q O/E = 1.0

¹ Median Post-procedure length of stay in STEMI patients. Exclusions: pt.'s discharged to Another Acute Care Facility; death

during procedure (ref:4340, 10894)

* Comparison reporting period is 04/01/20 through 03/31/21 75/84

Post-PCI Same Day Discharge - Electives




R4Q O/E = 1.1

¹ Elective patients discharged on the same day as procedure. Exclusions: mortalities and pt.'s discharged to Another Acute

Care Facility or AMA (ref:4971)

* Comparison reporting period is 04/01/20 through 03/31/21 76/84

Clinical Quality Goal Update August 2021





	FY 21 Clinical Quality Goals								
	Fiscal Year 2021 Higher is Better	FY21 Goal	FY20	Last 6 Months FY20	Health is our passion. Excellence is our focus. Compassion is our promise.				
SEP-1 (% Bundle Compliance)	74%	≥70%	67%	69%	Our Vision To be your world-class healthcare choice, for life				

Percent of patients with this serious infection complication that received "perfect care". Perfect care is the right treatment at the right time for our sepsis patients.

Lower is Better	July 2020	Aug 2020	Sept 2020	Oct 2020	Nov 2020	Dec 2020	Jan 2021	Feb 2021	Mar 2021	Apr 2021	May 2021	June 2021	Estimated Annual Number Not to Exceed to Achieve Goal*	FYTD SIR** (number of actual/ number expected)	FY21/ FY22 Goal	FY20
CAUTI Catheter Associated Urinary Tract Infection	1	0	1	1	1	1	0	1	0	3	1	1	20	52%↓ 0.542	≤0.727 ≤0.676	1.12
CLABSI Central Line Associated Blood Stream Infection	2	1	1	0	1	2	1	2	0	0	1	1	16	38% ↓ 0.745	≤0.633 ≤0.596	1.2
MRSA Methicillin-Resistant Staphylococcus Aureus	1	3	2	2	1	1	2	2	1	2	0	0	6	147%↑ 2.782	≤0.748 ≤0.727	1.02

*based on FY21 NHSN predicted

**Standardized Infection Ratio is the number of patients who acquired one of these infections while in the hospital divided by the number of patients who were expected.



Key Strategies Sepsis IN PROCESS ACTION:

- Exploring "Resident Sepsis Resource" for Coordinator off hours with Dr. Winston
- Sepsis handoff checklist or "Active Dashboard", which is used to identify any remaining CMS SEP-1 elements needed for the treatment of patients suffering from severe sepsis.
 - Checklist or active dashboard used as a handoff from nurse to nurse, and identifies the remaining elements needed to fulfill SEP-1 requirements.
 - Ideal for instances when a patient transitions from the ED to their respective inpatient bed, or upon transitioning from a previous inpatient location to a new inpatient location (e.g., patients transitioning to a higher level of care).

Expand All All Not Scanned Favorites D Timer (1)	P.1.7						Se Expand All A C			 10.000 	000.
				ne a device collects the data.			Code Sepsis Even	ts 📑 A		More -	PPP+.
) Timer (1)			vice collected data, re	eler to the 'Device Time' field.	1. X Dent si	novi Again	+ Sepsis Document	tation Start	Time		[Time Mark Orden]
	*	QuickBar				-	 Sepsis Bundle St Sepsis Bundle Er 		Mark	1	
ctive	× *	Blood pressure (BP)	D	MAP (mmHq)	DE	1	+ Sepsis Document	tation End		R Blood O	iture
() ED Sepsis E	Bundle 15m	Heart Rate					RN On-Going Ass	essments V			
Sepsis Bundle T	Timer	Respirations	. 0[Existing LDAs & V	Younds (0)		Antibiotics (iompiete
iepsis Note & E	Exemptions &	Temperature source		Temperature			Ns/Lines	8		Crystalloid Flui	is Complete
itals/I&O	¥	remperature source		phageal Temporal Artery		Laborer	Tubes/Drains	V	-	MIT.	
				ted or Documented Infection			Ainways		A) 5	USPECT AN IN	
OCT Results	 • A Nurse View 					File			- СК	TERIA	00.000
IAR	Situation Background ×	- ● ●	Discharge	× + Visit Summary		7.100	≡• ⊙	Flagged Events (0)		(D) Full scr	en @Print 20m
AAR	Situation Background X Allergies (3)			Visit Summary Selected Visit	_			Selected Visit: Last 30 days		(O) Full scri	en @Print 20n
Ign & Helt	Situation Background X All lengies (3) All visits sulfa drugs Zent XR		=• *	Visit Summary Selected Visit Service: Phone E Resuscitation Status: No resu	Encounter	07/01/2		Selected Visit: Last 30 days No results found		(0) Full series	en 👘 Print 200 a o 🗣 🗊 Q
MAR ign & Hele Specime Zi	Stuation Background × Allorgies (3) Allorgies (3) Allorgies (3) Allorgies (3) Suffa drugs Zerk XR. Zofran	Handoff X I	=* ^	Visit Summary Selected Visit Service: Phone E Resuscitation Status: No resul Advance Directive: No resul Isolation: No resul	Encounter ults found ults found ults found			Selected Visit: Last 30 days		(0) Full series	en @Print 20n
AR A ign & Hele S Specime abs	Situation Background X All lengies (3) All visits sulfa drugs Zent XR	Handoff X I	=• 0	Visit Summary Selected Visit Service: Phone E Resuscitation Status: No resul Advance Directive: No resul Activity Order: No resul Activity Order: No resul	Encounter uits found uits found uits found uits found uits found			Selected Visit: Last 30 days No results found Overdue Tasks (0)		(C) Full scr	en 👘 Print 200 a o 🗣 🗊 Q
AAR A ign & Heli 9 Specime abs H Lactate, E See instr	Stuation Background X Atlengies (3) At Yorks Suff a frugs Zefra RR Reasurements and Weights (0	Handoff X I	E* 0 E* 0	Visit Summary Selected Visit Service: Phone E Resuscitation Status: No resul Isolation: No resul Isolation: No resul Dati: No resul Pain Score: No resul Assistive Devices (0)	Encounter ults found ults found ults found			Selected Viuit: Last 30 days No results found Overdue Tasks (0) Selected Viuit: Last 24 hour No results found Media Gallery (0)		(a) Full ser	en 👘 Print 200 a o 🗣 🗊 Q
AAR ign & Hele Specime abs Loctate, E See Instr Collect St	Stuation Background X Allergies (3) Al Vala Al Vala Ulfa drugs Zefra RR Zofran Mensurements and Weights (0 Selected Val	Handoff X I	E* 0 E* 0	Visit Summary Selected Visit Service: Phone E Resuscitation Status: No resul Isolation: No resul Isolation: No resul Activity Order: No resul Diet: No resul	Encounter uits found uits found uits found uits found uits found			Selected Viait: Last 30 days No results found Overdue: Tasks (0) Selected Viait: Last 24 hour No results found Media Galilery (0) All Viaits: Last 30 days		i Terre d'Aller	en (10) Print 2001
AAR ign 8: Helk Specime abs E Lactate, E See instr Collect St L	Stauton Background X Altergiles (3) A Al Valas Dark drops Zerk XR Zofan Measurements and Weights (o Selected Vala Lines, Tablen, and Drains (o) Selected Val	Handoff X I	E* 0 E* 0	Visit Summary Selucid Visit Service: Phone E Resuscitation Status: No resul Advance Directive: No resul Diabaton: No resul Diabaton: No resul Pain Score: No resul Pain Score: No resul Adsistrie Devices (0) No results found Psychosocial Factors (0)	Encounter uits found uits found uits found uits found uits found			Selected Visit: Last 30 days No results found Overdure Tasks (0) Selected Visit: Last 24 hour No results found Media Gallery (0) All Visit: Last 30 days • Filter applied	5	C Source 2 doited a	en (10) Print 2001
AAR ign & Heli Specime 2 2 2 2 2 2 2 2 2 2 2 2 2	Studion Background X Attempties (2) A Voian Ad	Handoff X I	E* 0 E* 0 E* 0	Vicit Summuary Selicitei Viot Service: Phone E Resuscitation Status: No resul Advance Directive: No resul Solation: No resul Solation: No resul Pain Score: No resul Pain Score: No resul A Assistive Devices (0) No results Found	Encounter uits found uits found uits found uits found uits found		21 11:08	Selected Viait: Last 30 days No results found Overdue: Tasks (0) Selected Viait: Last 24 hour No results found Media Galilery (0) All Viaits: Last 30 days	5	(Q) Full scr	en (10) Print 2001
AAR ign & Hele Specime abs E Lactate, E See instr. Collect St N	Stauton Background X Altergines (2) Alf Verse and A torge and A torge and A torge A torget and A torget and A torget Selected Verse tensels froud tensels froud tensels froud tensels froud tensels froud tensels froud tensels froud tensels froud tensels for and tensels for an and tensels for an anti- tensel for an anti- tense	Handoff X I	E* 0 E* 0	Vicit Summary Selected Vait Service: Prove E Resuccitions Status: No read Statutor: No read Statutor: No read Statutor: No read Statutor: No read Advance Directive No readult found No readult f	Encounter uits found uits found uits found uits found uits found		21 11:06	Selected Viait: Last 20 days No results found Overdue Tasks: (0) Selected Viait: Last 24 hour No results found Media Galilery (0) Al Viait: Last 30 days • Fifter appled View Selection Clear Se	5	(Q) Full scr	en (10) Print 2001
AAR ign & Heli Specime abs Lactate, f See instr Collect St N	Studion Background X Attempties (2) A Voian Ad	Handoff X I	E* 0 E* 0 E* 0	Visit Summary Selector Voit Service: Phone E Resultation Status: In real Advance Directive: In the real Advance Directive: In the real Advance Directive: In the real Advance Directiv	Encounter uits found uits found uits found uits found uits found		21 11:08	Selected Viait: Last 20 days No results found Overdue Tasks: (0) Selected Viait: Last 24 hour No results found Media Galilery (0) Al Viait: Last 30 days • Fifter appled View Selection Clear Se	5	(Q) Full scr	en (10) Print 2001
AAR ign & Hell Specims abs Loctate E See hist Collect St N 1 1 1 1 1 1 1 1 1 1 1 1 1	Studion Badground X Alfonghes () Alfonghes () A	Randoff X 1	E* 0 E* 0 E* 0	Vicit Summary Selected Vait Service: A Priore E Resultation Status: A Forme E Resultation Status: A Former Southers' offer and the former Southers' offer and the former Det: Boreads Addated Detactors (o) Exelected Vait Selected Vait Evendences Ad Vaite Evendences	Encounter uits found uits found uits found uits found uits found		21 11:06	Selected Viait: Last 20 days No results found Overdue Tasks: (0) Selected Viait: Last 24 hour No results found Media Galilery (0) Al Viait: Last 30 days • Fifter appled View Selection Clear Se	5	(Q) Full scr	en (10) Print 2001
AAR ign & Hell Specims abs Loctate E See hist Collect St N 1 1 1 1 1 1 1 1 1 1 1 1 1	Stauton Background X Altergies (2) Al Verse Al	Randoff X 1	E* 0 E* 0 E* 0	Vidi Summary Setect Vat Service: Phone E Resucction Status: No read Datation Structure: No read Datation: No read Datation: No read Datation: No read Adatation Devices No reads found No	Encounter uits found uits found uits found uits found uits found		21 11:06	Selected Viait: Last 20 days No results found Overdue Tasks: (0) Selected Viait: Last 24 hour No results found Media Galilery (0) Al Viait: Last 30 days • Fifter appled View Selection Clear Se	5	(Q) Full scr	en (10) Print 2001
AAR ign & Hell Specims abs Loctate E See hist Collect St N 1 1 1 1 1 1 1 1 1 1 1 1 1	Studion Badground X Alfonghes () Alfonghes () A	Randoff X 1		Vidi Summary Setetad Vat Service: Phone E Resouction Status: No read Advince Directive No read Adving Vorder: No Vorde	Encounter uits found uits found uits found uits found uits found		21 11:06	Selected Viait: Last 20 days No results found Overdue Tasks: (0) Selected Viait: Last 24 hour No results found Media Galilery (0) Al Viait: Last 30 days • Fifter appled View Selection Clear Se	5	(Q) Full scr	en (10) Print 2001
AAR ign & Hell Specims abs Loctate E See hist Collect St N 1 1 1 1 1 1 1 1 1 1 1 1 1	Studion Badground X Alfonghes () Alfonghes () A	Randoff X 1		Vicit Summary Selected Vait Service: A Priore E Resultation Status: A Forme E Resultation Status: A Former Southers' offer and the former Southers' offer and the former Det: Boreads Addated Detactors (o) Exelected Vait Selected Vait Evendences Ad Vaite Evendences	Encounter uits found uits found uits found uits found uits found		21 11:06	Selected Viait: Last 20 days No results found Overdue Tasks: (0) Selected Viait: Last 24 hour No results found Media Galilery (0) Al Viait: Last 30 days • Fifter appled View Selection Clear Se	5	(Q) Full scr	en (10) Print 2001
VAR ign & Hele Specime abs E Lactate, E See instr Collect St N 1 1 1 1 1 1 1 1 1 1 1 1 1	Studion Badground X Alfonghes () Alfonghes () A	Randoff X 1		Vidi Summary Zeteral Vidi Service: Phone E Resouctions State: In the read Service: In the read Sections State: In the read Sections of the read Section of the read Section (I) In the read Section (I) In the read Section (I) Internation State: Internation Section Problems Al Vide C Internation Section Internation Internatio Internation Internation Internation Inter	Encounter uits found uits found uits found uits found uits found	97/91/2	21 11:06	Selected Viait: Last 20 days No results found Overdue Tasks: (0) Selected Viait: Last 24 hour No results found Media Galilery (0) Al Viait: Last 30 days • Fifter appled View Selection Clear Se	5	(Q) Full scr	en (10) Print 2001




Key Strategies CAUTI & CLABSI

- Gemba's! And trialing handoff process using Gemba elements
- Task force for retention management
- Letter to providers who were involved with a CAUTI event, going to physician leaders for approval
- EMR changes to improve catheter appropriateness, adherence to bundle elements and to manage retention
- New alternatives to catheter products trials
- Including peripheral IVs to critical care gemba (evaluating "just in case lines" and care practices)
- Evaluating new midline dressing kits (current kits missing necessary items)
- Education on CAUTI & CLABSI prevention for all residents completed and on annual schedule!
- Increasing midline insertion in ED through EM Resident and PICC team partnership



Key Strategies Planned Interventions to reduce MRSA Bloodstream infection


- 1. Hand Hygiene BioVigil and Non-BioVigil areas, 95% compliance and consistent use of the BioVigil system
- 2. High Risk Patient Decolonization
- Patients who are colonized with MRSA means they carry it in their nose or on your skin but are not sick with a MRSA infection. Hospitalization is a high risk time for patients, this MRSA that patients carry with them can travel to wounds or lungs, and other areas of patient's bodies that can lead to poor outcomes during hospitalization
- Decolonization therapy is the administration of. antimicrobial or antiseptic agents to eradicate or. suppress MRSA carriage. includes an Intranasal antibiotic or antiseptic (e.g., mupirocin, povidone-iodine) Topical antiseptic (e.g., chlorhexidine)
- For Kaweah this means:
 - Decolonization with CHG Bathing (topical antiseptic) for all at risk MRSA positive patients
 - Decolonization with Mupirocin (Antibiotic)





Key Strategies

Planned Interventions to reduce MRSA Bloodstream infection





FY22 Clinical Quality Goals

Our Mission Health is our passion. Excellence is our focus. Compassion is our promise.

> Our Vision To be your world-class healthcare choice, for life

Performance Measure	Baseline	FY22 Goal	FY23 Goal	FY24 Goal
Standardized Infection Ratio (SIR) CAUTI, CLABSI, MRSA (CMS Data)	CAUTI 0.84 CLABSI 1.33 MRSA2.53	CAUTI≤ 0.676 CLABSI ≤ 0.596 MRSA ≤ 0.727	tbd	tbd
Percent Sepsis Bundle Compliance (SEP-1) (CMS Data)	75% (July-Dec2020)	≥75%	≥80%	≥82%
Hospital Readmissions (%)	(FY2019) AMI – 12.34 COPD – 16.09 HF – 18.22 PN Viral/Bacterial – 14.13	AMI – 9.99 COPD – 10.30 HF – 11.66 PN Viral/Bacterial – 9.04	TBD	TBD
Decrease Mortality Observed/Expected Rates	(2019) AMI - 0.75 COPD – 2.40 HF – 1.78 PN Bacterial – 1.85 PN Viral – 1.34	AMI - 0.67 COPD – 1.00 HF – 1.14 PN Bacterial – 1.18 PN Viral - 0.96	TBD	TBD
Home Medication List Review of High Risk Patients (inpatient admission)	57% (Avg Oct 2020 and Feb 2021)	100%	100%	100%
Complete Initial Home Medication w/in 12 hours of Inpatient Admission	N/A	100%	100%	100%
Outpatient Medication Reconciliation w/in 30 days Post Discharge (MRP)	N/A	44%	55%	78%
Team Round Implementation	MICU currently does this	Design & Pilot on 1-2 units	Roll out expectations for 2 additional units and measure at 6 months % adherence	80% Adherence for 3-4 units and roll out for units with hospital- based groups and measure at 6 months % adherence



Questions?

Live with passion.

Health is our passion. Excellence is our focus. Compassion is our promise.

